NASDAQ: CLRB - Cellectar Biosciences, Inc.

Rentabilité sur six mois: -85.75%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Cellectar Biosciences, Inc.


À propos de l'entreprise Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.

plus de détails
Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

IPO date 2005-11-10
ISIN US15117F8077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.cellectar.com
Цена ао 0.3638
Changement de prix par jour: 0% (0.2936)
Changement de prix par semaine: +19.5% (0.2457)
Changement de prix par mois: -12.83% (0.3368)
Changement de prix sur 3 mois: +18.34% (0.2481)
Changement de prix sur six mois: -85.75% (2.06)
Changement de prix par an: -90.85% (3.21)
Evolution du prix sur 3 ans: -52.71% (0.6209)
Evolution du prix sur 5 ans: -77.53% (1.3065)
Evolution des prix depuis le début de l'année: -79.89% (1.46)

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0.7587 9
P/E 0 0
EV/EBITDA 0.2308 10
Total: 4.88

Efficacité

Nom Signification Grade
ROA, % -237.45 0
ROE, % -689.12 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0.5857

Devoir

Nom Signification Grade
Debt/EBITDA -0.0095 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -187.41 0
Rentabilité Ebitda, % 234.05 10
Rentabilité EPS, % -83.89 0
Total: 6

Établissements Volume Partager, %
Nantahala Capital Management, LLC 2701156 8.37
Rosalind Advisors, Inc. 2005658 6.22
AIGH Capital Management LLC 1915220 5.94
Adar1 Capital Management, LLC 1378082 4.27
Worth Venture Partners, LLC 693909 2.15
Vanguard Group Inc 482890 1.5
Acuta Capital Partners LLC 477500 1.48
Citadel Advisors Llc 69007 0.21
Geode Capital Management, LLC 68870 0.21
Blackrock Inc. 57042 0.18



Superviseur Titre d'emploi Paiement Année de naissance
Mr. James V. Caruso President, CEO & Director 1.14M 1959 (66 années)
Mr. Chad J. Kolean CPA VP, CFO & Secretary 711.23k 1964 (61 année)
Mr. Jarrod Longcor Chief Operating Officer 854.24k 1973 (52 année)
Mr. Darrell Shane Lea Chief Commercial Officer N/A 1974 (51 année)
Dr. Andrei Shustov M.D. Senior Vice President of Medical N/A 1972 (53 année)

Adresse: United States, Florham Park. NJ, 100 Campus Drive - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.cellectar.com